Dendritic cell-derived exosomes in cancer immunotherapy: Exploiting nature's antigen delivery pathway

Expert Review of Anticancer Therapy

Volumn 5, Issue 3, 2005, Pages 537-547

  Delcayre, Alain ^a   Shu, Helen ^a   Le Pecq, Jean Bernard ^a  

^a Anosys Inc   (United States)

Author keywords

Antigen; Cancer; Dexosomes; Exosomes; Immunotherapy; Tumor; Vaccine

Indexed keywords

CANCER VACCINE; CD1 ANTIGEN; CD1B ANTIGEN; CD1C ANTIGEN; CD1D ANTIGEN; CD81 ANTIGEN; CD86 ANTIGEN; CD9 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; T6 ANTIGEN; TETRASPANIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BLOOD CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ISOLATION; CELL VACUOLE; CELLULAR IMMUNITY; CLINICAL OBSERVATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; EX VIVO STUDY; EXOSOME; FEASIBILITY STUDY; HUMAN; IMMUNOSTIMULATION; INTRACELLULAR TRANSPORT; LEUKAPHERESIS; LIPID BILAYER; LUNG NON SMALL CELL CANCER; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; REVIEW; SIDE EFFECT; THERMOSTABILITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DENDRITIC CELLS; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 21244454869     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.3.537     Document Type: Review

References (60)

1. van der Bruggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T-cells. Immunol. Rev. 188, 51-64 (2002).
2. Dausset J. The major histocompatibility complex in man. Science 213(4515), 1469-1474 (1981).
3. Rosenberg SA. In: Principles and Practice of the Biological Therapy of Cancer. Lippincott Williams & Wilkins, PA, USA (Third Edition) (2000).
4. Morse MA, Clay TM, Lyerly HK. In: Handbook of Cancer Vaccines. Humana Press, NJ, USA (2004).
5. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance and tumor immune escape. J. Cell Physiol. 195(3), 346-351 (2003).
6. Théry C, Zitvogel Z, Amigorena S. Exosomes: composition, biogenesis and function. Nature Rev. Immunol. 2(8), 569-579(2002).
7. Lurquin C, Lethe B, DePlaen E. et al. Contrasting frequencies of antitumor and anti-vaccine T-cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201(2), 249-257 (2005).
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
9. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nature Med. 10(5), 475-480 (2004).
10. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101(Suppl. 2), 14639-14645 (2004).
11. Albertsson PA, Basse PH, Hokland M et al. NK cells and the tumor microenvironment: implications for NK-cell function and antitumor activity. Trends Immunol 24(11), 603-609 (2003).
12. Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. 5(4), 405-411 (1999).
13. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195(3), 343-351 (2002).
14. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J. Immunol. 172(3), 1333-1339 (2004).
15. Barral AM, von Herrath MG. Exosomes: specific intercellular nano-shuttles? Curr. Immunol. Rev. 1, 1-6 (2005)
16. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signalling device. J. Cell Sci. 113, 3365-3374 (2000).
17. Laulagnier K, Motta C, Hamdi S et al. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem. J. 380, 161-171 (2004).
18. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16(4), 415-421 (2004).
19. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20(1), 22-27 (2005).
20. Lamparski HG, Metha-Damani A, Yao JY et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods 270(2), 211-226 (2002).
21. Wubbolts R, Leckie RS, Veenhuizen PT et al. Proteomic and biochemical analyses of human B cell-derived exosomes, potential implications for their function and multivesicular body formation. J. Biol. Chem. 278(13), 10963-10972 (2003).
22. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Ann. Rev. Cell Dev. Biol. 19, 397-422 (2003).
23. Tarrant JM, Robb L, van Spriel AB, Wright MD. Tetraspanins: molecular organizers of the leukocyte surface. Trends Immunol. 24(11), 610-617 (2003).
24. Thery C, Boussac M, Veron P et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166(12), 7309-7318 (2001).
25. Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 33(2), 522-531 (2003).
26. + T cells by dendritic cell-derived exosomes. Nature Immunol. 3, 1156-1162 (2002).
27. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int. Immunol. 14(7), 713-722 (2002).
28. Hsu DH, Paz P, Villaflor G et al. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. 26(5), 440-450 (2003).
29. Andre F, Chaput N, Schartz NE et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172(4), 2126-2136 (2004).
30. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. USA 100(19), 10592-10597 (2003).
31. Nguyen DG, Booth A, Gould SJ, Hildreth JE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J. Biol. Chem. 278(52), 52347-52354 (2003).
32. Morita E, Sundquist WI. Retrovirus budding. Ann. Rev. Cell Dev. Biol. 20, 395-425 (2004).
33. Masciopinto F, Giovani C, Campagnoli S et al. Association of hepatitis C virus envelope proteins with exosomes. Eur. J. Immunol. 34(10), 2834-2842 (2004).
34. Pelchen-Matthews A, Raposo G, Marsh M. Endosomes, exosomes and Trojan viruses. Trends Microbiol. 12(7), 310-316 (2004).
35. Flanagan J, Middeldorp J, Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J. Gen. Virol. 84, 1871-1879 (2003).
36. Taylor DD, Gercel-Taylor C. Tumor-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer. 92(2), 305-311 (2005).
37. Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4(5), 594-600 (1998).
38. Chaput N, Schartz NE, Andre F et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 172(4), 2137-2146 (2004).
39. Aline F, Bout D, Amigorena S, Roingeard P, Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect. Immun. 72(7), 4127-4137 (2004).
40. Brandle D, Bilsborough J, Rulicke T, Uyttenhove C, Boon T, Van den Eynde BJ. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28(12), 4010-4019 (1998).
41. Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 76(10), 1503-1510 (2003).
42. Alexander J, del Guercio MF, Maewal A et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 164(3), 1625-1633 (2000).
43. Patel S, Metha-Damani A, Shu H, Le Pecq JB. An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy. Biotech. Bioeng. (2005) (In Press).
44. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388(6644), 782-787 (1997).
45. Bhardwaj N, Friedman SM, Cole BC, Nisanian AJ. Dendritic cells are potent antigen-presenting cells for microbial superantigens. J. Exp. Med. 175(1), 267-273 (1992).
46. Bhardwaj N, Young JW, Nisanian AJ, Baggers J, Steinman RM. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T-cell responses. J. Exp. Med. 178(2), 633-642 (1993).
47. Paz P, Paranjpe G, Villaflor G, Hsu DH, Le Pecq JB. A validated potency assay for dexosomes, a novel acellular product for cancer therapy. 19th Annual Meeting International Society for Biological Therapy of Cancer. Abstract 86 (2004).
48. Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived exosomes: results of the first Phase I clinical trial. J. Transl. Med. 3(1), 10 (2005).
49. Morse MA, Garst J, Osada T et al. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3(1), 9 (2005).
50. Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for cross-priming. Nature Med. 7(3), 297-303 (2001).
51. Andre F, Schartz NE, Chaput N et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20(Suppl. 4), A28-31 (2002).
52. Andre F, Schartz NE, Movassagh M et al. Malignant effusions and immunogenic tumor-derived exosomes. Lancet 360(9329), 295-305 (2002).
53. Altieri SL, Khan AN, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J. Immunother. 27(4), 282-288 (2004).
54. Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195(10), 1303-1316 (2002).
55. Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol. Hum. Reprod. 11(1), 35-41 (2005).
56. Janowska-Wieczorek A, Wysoczynski M, Kijowski J et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113(5), 752-760 (2005).
57. Whiteside TL. Tumor-derived exosomes or microvesicles: another mechanism of tumor escape from the host immune system? Br. J. Cancer 92(2), 209-211 (2005).
58. Gutwein P, Stoeck A, Riedle S et al. Cleavage of l1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin. Cancer Res. 11(7), 2492-2501 (2005).
59. Raulet D. Interplay of natural killer cells and their receptors with the adaptive immune response. Nature Immunol. 5(10), 994-1002 (2004).
60. Vivier E, Malissen B. Innate and adaptive immunity: specifications and signalling hierarchies revisited. Nature Immunol. 6(1), 17-21 (2005).